<html><body><pre>
[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5663 Introduced in House (IH)]

&lt;DOC&gt;






117th CONGRESS
  1st Session
                                H. R. 5663

To prohibit the Secretary of Health and Human Services from restricting 
direct access by health care facilities to COVID-19 monoclonal antibody 
                               therapies.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                            October 21, 2021

   Mrs. Harshbarger (for herself, Mr. DesJarlais, Mr. Burchett, Mr. 
  Fleischmann, Mr. Posey, Mr. Babin, Mrs. Cammack, Mr. Roy, Mr. Rose, 
 Mrs. Miller-Meeks, Mr. Perry, Mr. Gohmert, Mr. Mast, Mr. Steube, Mr. 
 Jackson, Mr. Williams of Texas, Mr. Austin Scott of Georgia, and Mr. 
   Donalds) introduced the following bill; which was referred to the 
                    Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
To prohibit the Secretary of Health and Human Services from restricting 
direct access by health care facilities to COVID-19 monoclonal antibody 
                               therapies.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Treatment Restoration for Emergency 
Antibody Therapeutics Act'' or the ``TREAT Act''.

SEC. 2. PROHIBITION ON RESTRICTIONS ON DIRECT ACCESS TO COVID-19 
              MONOCLONAL ANTIBODY THERAPIES.

    (a) In General.--Notwithstanding any other provision of law, the 
Secretary of Health and Human Services (referred to in this section as 
the ``Secretary'') may not implement or continue in effect any policy 
that would restrict hospitals or other appropriate health care 
facilities from ordering and receiving COVID-19 monoclonal antibody 
therapies directly from manufacturers and distributors of such 
therapies.
    (b) Nullification of Certain Policy.--Pursuant to subsection (a), 
effective on the date of enactment of this Act, the policy under which 
the Secretary required hospitals and other facilities to work through 
State or territorial governments to receive supplies of COVID-19 
monoclonal antibody therapies allocated by the Secretary to such States 
or territories, announced by such Secretary on September 13, 2021, 
shall have no force or effect.
                                 &lt;all&gt;
</pre></body></html>
